Articles related to Oncology, Surgical

The recent suspension of Dr. Benjamin Neel, former director of NYU’s Perlmutter Cancer Center, underscores the importance of academic integrity in the medical field. As healthcare professionals, it’s crucial to uphold the highest standards of conduct in our research.

The recent phase 3 trial has demonstrated the potential of amivantamab as a first-line treatment option for patients with advanced NSCLC with EGFR exon 20 insertions. The combination of amivantamab and chemotherapy significantly improved progression-free survival compared to chemotherapy alone.

With 40% of us expected to develop cancer in our lifetime and 20% likely to die from it, the need for advanced care is more urgent than ever. This collaboration between Dana-Farber and BIDMC represents a significant step towards meeting this need.

The study underscores the potential of perioperative durvalumab in combination with neoadjuvant chemotherapy to significantly improve event-free survival and pathological complete response in patients with resectable NSCLC.

The discovery that chemotherapy-induced cognitive impairment, or “chemobrain,” may be linked to an excess of calcium inside cells opens new avenues for potential therapies. This breakthrough could lead to treatments that restore cognition in patients experiencing these symptoms.

The approval of Combogesic IV, backed by data from two phase 3 studies, signifies a major breakthrough in our ongoing efforts to provide effective and safer alternatives to opioids for postoperative pain management.